NCT01318421View on ClinicalTrials.gov

A Study of ELND002 in Patients With Relapsing Forms of Multiple Sclerosis

PHASE1TerminatedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

December 31, 2010

Primary Completion Date

December 31, 2012

Conditions
Multiple Sclerosis
Interventions
DRUG

ELND002

Sponsors
All Listed Sponsors
lead

Elan Pharmaceuticals

INDUSTRY